Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity

Günay, Murat; Şekeroğlu, Mehmet Ali; Bardak, Handan; Çelik, Gökhan; Esenülkü, Cenap Mahmut; Hekimoğlu, Emre; Bardak, Yavuz

doi:10.3109/09273972.2016.1159232

Cited by 26 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lee et al found that AL did not differ among different treatment groups. Gunay et al 34 reported that in children who receive anti-VEGF drug therapy, the AL might be related to the development of myopia and is not related to the ACD or LT. The Bevacizumab Eliminates the Angiogenic Threat for ROP (BEAT-ROP) believes that anti-VEGF drug treatment may facilitate the continuation of the local growth factor expression and signalling pathways, allowing the anterior segment to develop normally.…”

Section: Open Accessmentioning

confidence: 99%

Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis

Kong

Ming

2021

BMJ Open

View full text Add to dashboard Cite

ObjectiveTo determine the effects of the intraocular injection of antivascular endothelial growth factor (anti-VEGF) drugs on the refractive status of infants with retinopathy of prematurity (ROP).DesignSystematic review and meta-analysis of the refractive status of infants with ROP who receive anti-VEGF drugs.Data sourcesThe PubMed, Web of Science and Embase databases and the ClinicalTrials.gov website were searched up to June 2020.Eligibility criteria when selecting studiesWe included randomised controlled trials (RCTs) and observational studies that compared refractive errors between anti-VEGF drug and laser therapies.Data extraction and synthesisData extraction and risk-of-bias assessments were conducted by two independent reviewers. We used a random-effect model to pool outcomes. The outcome measures were the spherical equivalents, axial length (AL), anterior chamber depth (ACD) and lens thickness (LT).ResultsThirteen studies involving 1850 eyes were assessed: 914 in the anti-VEGF drug group, and 936 in the control (laser) group. Children who received anti-VEGF drug treatment had less myopia than those who received laser therapy (mean difference=1.80 D, 95% CI 0.97 to 2.63, p＜0.0001, I2=78%). The AL, ACD and LT did not reach statistical significance difference between the two groups. The current evidence indicates that the refractive safety in children with ROP is better for anti-VEGF drug treatment than for laser therapy.ConclusionsThis meta-analysis indicates that anti-VEGF drug therapy results in less myopia compared with laser therapy. However, there are relatively few published articles on refractive errors in ROP, and so high-quality and powerful RCTs are needed in the future.PROSPERO registration numberCRD42020160673.

show abstract

Section: Open Accessmentioning

confidence: 99%

Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis

Kong

Ming

2021

BMJ Open

View full text Add to dashboard Cite

show abstract

“…Intravitreal injection of anti-vascular endothelial growth factor (VEGF) antibodies is an alternative to laser treatment in severe cases of ROP, such as aggressive posterior ROP (APROP), and ROP in zone 1 or posterior zone 2 [6]. Different from laser treatment, anti-VEGF antibody injection may allow maturation of the peripheral retina and anterior segment, and reports indicate better structural and visual outcomes (median VA of 0.3 log-MAR at around 2 years after treatment for type 1 ROP [7]) and a reduced incidence of myopia compared with laser [6,[8][9][10][11][12][13][14][15][16], though not all studies support these findings [17,18]. Anti-VEGF antibody therapy may require more than one treatment application, with reported retreatment rates ranging from 4 to 14% [6,9,11,12], though higher rates of 27% have also been reported [7].…”

Section: Introductionmentioning

confidence: 99%

Retinopathy of prematurity in the United Kingdom: retreatment rates, visual and structural 1-year outcomes

Adams

Bunce

Xing

et al. 2018

Eye

View full text Add to dashboard Cite

show abstract

“…They are also in agreement with Harder et al 9 and other groups who have published similar retrospective studies that demonstrated a definite correlation between IVB therapy and a reduced prevalence of myopia. [6][7][8]10 Overall, in both zone 1 and 2 disease (Fig. 5B), IVB therapy was associated with a lower prevalence of myopia and high myopia compared with laser treatment.…”

Section: Discussionmentioning

confidence: 89%

“…Most studies, including the BEAT-ROP trial, have demonstrated a reduced prevalence of myopia and high myopia among IVBtreated infants compared with laser-treated infants with type I ROP. [6][7][8][9][10][11] Gunay et al reported a significantly higher prevalence of high myopia in infants with zone 1 ROP vs zone 2 disease and an increase prevalence of high myopia in those treated with laser photocoagulation compared to the IVB treated group. 12 None of the previous studies examined the pattern of longitudinal refractive error development among infants with type 1 ROP treated with IVB.…”

Section: Introductionmentioning

confidence: 99%

Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity

Simmons

Wang

Leffler

et al. 2021

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose To compare the patterns of longitudinal refractive error development during the first 3.5 years in children with severe retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB) or laser photocoagulation. Methods This prospective cohort study enrolled extremely preterm infants (birth weight < 1000 g, gestational age 23–27 weeks) with type 1 ROP from multiple hospitals in Dallas between 1999 and 2017; IVB group (N = 22); laser group (N = 26). Cycloplegic retinoscopy was conducted from 0.04 years corrected age and every 0.5 to 1.0 years thereafter until 3.5 years old. Right eye spherical equivalent (SEQ) and astigmatism, anisometropia, and better-eye visual acuity were analyzed over time. Results In all children, both eyes were treated with the same modality. At the final visit, the prevalence of myopia (SEQ ≤ −1D) was 82.7% in the laser group and 47.7% in the IVB group ( P < 0.05) with a mean SEQ of −8.0D ± 5.8D in the laser group versus −2.3D ± 4.2D in the IVB group ( P < 0.001). Longitudinal SEQ were best fit with a bilinear model. Before one year, the rate of SEQ change was −5.0D/year in the laser group, but only −3.5D/year in the IVB group (T = −5.14, P < 0.001); after one year, there was a significant flattening of these slopes (T = 6.23, P < 0.001). Anisometropia in the IVB group was significantly less than in the laser group ( P < 0.05). Final visual acuity in both groups was similar at 0.47 logMAR (∼ 20/60). Conclusions Children with severe ROP treated with IVB developed less myopic refractive error than those treated with laser largely because of a slower rate of refractive change during the first year of life. Translational Relevance These findings may inform decisions regarding ROP treatment timing and modality.

show abstract

Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity

Abstract: The study showed no significant difference of SE between the groups. High myopia was only present among the treated infants either with IVB or laser. Infants who received laser treatment significantly had thicker lenses.

Cited by 26 publications

References 22 publications

Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis

Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis

Retinopathy of prematurity in the United Kingdom: retreatment rates, visual and structural 1-year outcomes

Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity

Contact Info

Product

Resources

About